Study of rhASB in Patients With Mucopolysaccharidosis VI

A Multicenter, Multinational Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With Mucopolysaccharidosis VI

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

Inclusion Criteria:

• Patient consent
• Patient must have successfully completed study ASB-03-05, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions
• If female of childbearing potential, patient must have a negative pregnancy test

Exclusion Criteria:

• Pregnant or lactating patient
• Patient has received an investigational drug within 30 days prior to study enrollment
• Patient is unwilling or unable to travel to the primary site for periodic assessments